Lumos Diagnostics Holdings (ASX:LDX) received confirmation of Medicare reimbursement coverage in the US from two additional Medicare administrative contractors, First Coast Service Options and Noridian Healthcare Solutions, according to a Wednedsay Australian bourse filing.
The firm's FebriDx point-of-care diagnostic test will be included in the Medicare fee schedule of the contractors at at $41.38 per test retroactively from April 1.
Its shares jumped 4% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.